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Summary
Backgroud: After the publication of DIG trial, the
therapeutic target of serum digoxin concentration
(SDC) for the treatment of heart failure (HF) has
been lowered (0.40–1.00 ng/ml). However, the ma-
jority of equations to calculate digoxin dosages were
developed for higher SDCs. Recently, a new equa-
tion was validated in Asian population for low SDCs
by Konishi et al., but results in Caucasians are
unknown.
Aim: This study was aimed to test the Konishi equa-
tion in Caucasians specifically targeting low SDCs.
Furthermore, the Konishi equation was compared
with other frequently used equations.
Design: This was a prospective, multicenter study.
Methods: Clinically indicated digoxin was given
in 40 HF patients. The dosage was calculated
with the Konishi equation. The SDC was measured
at 1 and 6 months after starting digoxin. Adherence
to digoxin was monitored with a specific
questionnaire.
Results: After exclusion of patients admitting poor
adherence, we found a reasonable correlation be-
tween predicted and measured SDC (r=0.48;
P< 0.01) by the Konishi equation. Excluding pa-
tients with poor adherence and relevant worsening
of renal function, the measured SDC (n=54 meas-
urements) was within the pre-defined therapeutic
range in 95% of the cases. The mean, maximal
and minimal measured SDC were 0.690.19,
1.00 and 0.32 ng/ml, respectively. The correlation
was weaker for the Jelliffe, the Koup and Jusko,
and the Bauman equations.
Conclusions: This study supports the clinical validity
of the Konishi equation for calculating individual
digoxin dosage in Caucasians, targeting SDCs
according to current HF guidelines.
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Introduction
Despite advances in heart failure (HF) treatment and
validation of newer drugs such as b-blockers,
ACE-Inhibitors, AT-II antagonists and aldosterone
antagonists, digoxin still plays an important role for
treatment of HF patients who remain significantly
symptomatic.1 Based on post hoc analysis of the
DIG trial, the optimal therapeutic level for serum
digoxin concentration (SDC) has been lowered sub-
stantially as compared to previous recommenda-
tions, since even SDCs in the former therapeutic
range (i.e. 1.2 ng/ml) have been found to increase
mortality.2–4 However, most of the equations to
calculate the individual dosage of digoxin were
tested for SDCs in the former therapeutic range.5–7
Konishi et al.8 developed a new equation tested for
low SDCs, which was shown to be more accurate
as compared to prior equations. However, this equa-
tion was tested in Asians, who may have a differ-
ent pharmacokinetic of digoxin as compared to
Caucasians.9,10 The present study is therefore
aimed to test the Konishi equation in Caucasian
patients, specifically targeting a range of SDC as
recommended by current guidelines for treatment
of HF.1 Additionally, we compared the Konishi
equation with some of the most frequently used
equations, which were tested for higher SDCs.5–7
Notably, during the course of the current study,
another equation targeting low SDCs has been
proposed by Bauman et al.11 Therefore, we also
compared the Konishi equation with this equation.
Methods
Study design and patient population
This was a prospective, multicenter study conducted
at the University Hospital of Basel and the Regional
Hospitals of Locarno and Lugano, Switzerland,
betweenOctober 2006 andMay 2009. Forty patients
with symptomatic HF and a clinical indication for
digoxin according to the Guidelines of the Task
Force for Diagnosis and Treatment of Chronic Heart
Failure of the European Society of Cardiology were
placed on digoxin.12 The primary aim of the study
was to assess adherence to the medical regime in HF
patients based on a specific questionnaire (CARDIA
questionnaire), and the measurement of SDC during
follow-up. Details of this study have been described
previously.13 The current study is a post hoc analysis
aimed to test the clinical validity of the Konishi equa-
tion to calculate the individual digoxin dosage.
Inclusion criteria were symptomatic HF NYHA
class 2, systolic left ventricular dysfunction (LVEF
45%) and age of 18 years. Exclusion criteria were
mainly related to absolute or relative contraindica-
tion to digoxin, including severe renal insufficiency
(creatinine clearance 30ml/min, estimated by
Cockcroft–Gault), AV-block grade II or III without
pacemaker, sinus bradycardia (resting heart rate
<50 beats/min.) without pacemaker, hypokalemia
(<3.5mmol/l) or hypercalcemia (>2.64mmol/l) not
correctable with medical treatment, acute coronary
syndrome <1 month, hypertrophic cardiomyopathy,
pre-excitation syndromes, severe dementia, preg-
nancy, unwillingness or inability to give informed
consent and concomitant use of drugs known to
have a relevant pharmacokinetic interaction with
digoxin, except for spironolactone, which has been
shown to have limited interaction with digoxin.8 The
study complies with the Declaration of Helsinki
and was approved by the local ethics committees.
All patients gave written informed consent.
Dosage of digoxin and follow-up
The individual dosage of digoxin was calculated as
proposed by Konishi et al.8 using the following
equation:
Daily dosage of digoxin (ug/day)
¼ SDC (ng/ml) ½2:22 Ccr (ml/min.Þ þ 25:7:
where SDC is the target SDC and Ccr is the esti-
mated clearance of creatinine as calculated with
the Cockcroft–Gault equation.8,14
The target SDC ranged between 0.60 and
0.80 ng/ml depending on the renal function and the
available dosages of digoxin pills (0.125 and
0.250mg). The pre-defined therapeutic range of
SDC was between 0.40 and 1.00 ng/ml, as recom-
mended by recent guidelines.1 All patients were
instructed to take their digoxin pills regularly
between 08:00 and 10:00. All serum digoxin meas-
urements were performed in the early afternoon
(between 14:00 and 16:00) in order to measure
a steady state concentration. The SDC was deter-
mined with enzyme immunoassay [VIDAS
Digoxin, BioMe´rieux SA, France in the centers of
Locarno and Lugano (17 patients), and COBAS,
Roche-Diagnostics, GmbH, Germany in the center
of Basel (23 patients)]. After baseline assessment
and introduction of digoxin treatment, patients
were followed for 6 months with follow-up visits
and measurement of the SDC after 1 and 6 months.
Detailed medical history, clinical and laboratory
examination, including SDC, creatinine levels and
electrolytes, were performed at baseline and at
follow-up visits. All patients were asked to complete
a structured and validated questionnaire about their
adherence to medical treatment at each follow-up
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visit (CARDIA Questionnaire).15 The questionnaire
consisted of the following question: ‘In the past
month, how often did you take your medications
as the doctor prescribed? (i) all of the time (100%);
(ii) nearly all of the time (90%); (iii) most of the time
(75%); (iv) about half the time (50%); and finally (v)
less than half the time (<50%)’. Poor adherence
was defined as a medication intake of 75%.
Comparison with prior equations
The Konishi equation, which was used to calculate
the individual dosage of digoxin in the current study,
was compared with the equations formulated
by Jelliffe et al.,5,6 Koup and Jusko et al.7 and the
most recently developed equation by Bauman
et al.11 (Table 1).
Statistics
Continuous data are presented as mean SD or
median (interquartile range) as appropriate.
Categorical data are presented as numbers and per-
centages. The correlation between the measured
and the predicted SDC by the different equations
was tested with a linear regression model and
Bland–Altman analysis. The comparison between
the measured and the predicted SDC were also
tested in terms of the root mean square error.
Potential interactions between renal function, and
differences between measured and predicted SDC
were tested with a linear regression model.
Interaction of predicted and measured SDC with
other baseline characteristics were tested using the
Fisher’s test for nominal variables. Continuous vari-
ables were tested using the Student’s t-test or the
Mann–Whitney U-test as appropriate. Differences
in measured SDC between patients with stable
renal function and good adherence, patients with
poor adherence and patients with relevant worsen-
ing of renal function were evaluated with the
Mann–Whitney test. A P-value of 0.05 was con-
sidered statistically significant. Analyses were per-
formed using the commercially available statistical
package SPSS version 15.0.
Results
The baseline characteristics of the 40 patients
included in the study are shown in Table 2. The
median age of the patients was almost 70 years
and the mean estimated clearance of creatinine
was 60ml/min., indicating a high prevalence of
patients with chronic kidney disease. The first
follow-up visit after 1 month was performed in all
patients. The second follow-up visit was performed
in 31 patients: one patient died because of sepsis,
six patients withdrew consent and in two patients
digoxin was stopped by the general practitioner be-
cause of presumed digoxin related side effects (one
patient had a symptomatic bradycardia and one pa-
tient had minor gastrointestinal side effects). Of note,
the SDCwas in the therapeutic range in the latter two
patients at visit month 1. Thus, 71 measurements of
the SDC were performed in these 40 patients.
Digoxin dosage and correlation between
the measured and the predicted SDC by
the Konishi equation
The daily dosages of digoxin based on the Konishi
equation are shown in Table 3.
Overall, 56 out of 71 measured SDC (79%)
were within the pre-defined therapeutic range
(0.40–1.00 ng/ml). Ten (14%) measured SDC (in
eight patients) were within the sub-therapeutic
range (<0.40 ng/ml) and five (7%) measured SDC
(in five patients) were within the supra-therapeutic
range (>1.00 ng/ml). The mean, maximal and
minimal measured SDC were 0.69 0.31, 1.70
and 0 ng/ml, respectively.
Table 1 Equations to calculate the dosage of digoxin
Author Equation
Konishi SDC (ng/ml) = digoxin dosage (ug/day)/[2.22Ccr (ml/min) + 25.7]
Jelliffea SDC (ng/ml) =0.416+ (0.185TBS)
Koup and Juskob SDC (ng/ml) = [F dosage of digoxin (ug/day) 1000]/[(1.303Ccr) +Cnr] 
Baumanc SDC (ng/ml) = 1.345+ (0.287 dose of digoxin) – (0.007Ccr) – (0.011 IBW)
Ccr, estimated creatinine clearance by Cockcroft–Gault for all equations.
aTBS ¼ðdaily dosage of digoxin=½14þ Ccr=5ð Þ=100Þ=BW, BW: body weight (both, total BW and ideal BW as calculated by
Devine were used as proposed by Jelliffe).
bF: bioavailability of oral digoxin (=0.75); Cnr: non-renal clearance of digoxin (=41ml/min); : dosing interval (=1440min/day).
cIBW: body weight as calculated by the method of Devine. Dose of digoxin is coded as 1 = 0.0625, 2 = 0.125 and
3=0.250mg/day.
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Of note, six patients admitted poor adherence to
medical regime with the CARDIA-Questionnaire.
Among patients with sub-therapeutic SDC (n=8),
five admitted poor adherence (seven of 10 SDC in
the sub-therapeutic range). All patients with supra-
therapeutic SDC (n=5) experienced a relevant wor-
sening of the renal function during follow-up (five of
five SDC in the supra-therapeutic range), defined as
a reduction of the estimated creatinine clearance
>20%. In none of the patients, the sub-therapeutic
SDC could be explained by an improvement in
renal function or the concomitant use of drugs
with a pharmacokinetic interaction.
After exclusion of SDCs measured in patients
admitting poor adherence (six patients, eight
SDCs), patients experiencing a relevant worsening
of renal function (eight patients, eight SDC) or
having both, poor adherence and worsening of
renal function (one patient, one SDC) a total of
54 SDC measurements were analyzed, of which
51 (95%) were within the therapeutic, three (5%)
within the sub-therapeutic and 0 (0%) within
the supra-therapeutic range, respectively. In this
cohort the mean, maximal and minimal measured
SDC were 0.69 0.19, 1.00 and 0.32 ng/ml, re-
spectively. Differences in measured SDCs among
patients with stable renal function and good adher-
ence, patients admitting poor adherence and pa-
tients experiencing a relevant worsening of the
renal function, are shown in Figure 1. The SDC
Table 2 Baseline characteristics
Total (n=40)
Male gender, n (%) 33 (83)
Age (years), mean SD 69 12
BMI (kg/m2), mean SD 26.8 5.0
Creatinine (mmol/l), mean SD 116 38
Estimated creatinine clearance
(ml/min), mean SD
57 23
Chronic kidney disease
Stage 2 (%) 10 (25)
Stage 3 (%) 28 (70)
BNP (pg/ml), median/IQR 517 (250–1020)
LVEF (%), mean SD 30 7
Systolic blood pressure (mmHg)
mean SD
122 18
Diastolic blood pressure (mmHg)
mean SD
71 12
Heart rate (beats pro minute)
mean SD
72 10
Coronary artery disease (%) 26 (65)
Prior hospitalization for HF (%) 26 (65)
Risk factors
Diabetes (%) 16 (49)
Hypercholesterolemia (%) 19 (48)
Hypertension (%) 27 (68)
Family history (%) 10 (25)
Smoking (%) 9 (23)
Medication
Aspirin (%) 20 (50)
b-blockers (%) 36 (90)
ACE-inhibitors (%) 25 (63)
AT-II antagonists (%) 17 (43)
Aldosterone antagonists (%) 25 (63)
Loop diuretics (%) 31 (78)
Oral anticoagulation (%) 20 (50)
Statins (%) 27 (68)
BMI: body mass index (kg/m2); IQR: interquartile range;
Chronic kidney disease Stages 2 and 3, estimated
glomerular filtration rate of 60–89ml/min/1.73m2 and
30–59ml/min/1.73 m2, respectively; BNP: brain natriuretic
peptide; LVEF: left-ventricular ejection fraction; ACE:
angiotensin converting enzyme; AT-II: angiotensin II.
Figure 1. Differences in measured SDC (ng/ml) among
patients with good medical adherence and stable renal
function (1), patients with poor medical adherence (2)
and patients with relevant worsening of renal function
(3) during follow-up.
Table 3 Digoxin dosage
Total (n=40)
Digoxin dosage at baseline (mg/day),
mean SD
0.105 0.039
Digoxin dosage at baseline (mg/day) (%)
0.0625a 12 (30)
0.089b 9 (23)
0.125c 15 (37)
0.188d 4 (10)
aOne pill of digoxin 0.125mg every other day.
bOne pill of digoxin 0.125mg 5 day/week.
cOne pill of digoxin 0.125mg/day.
dOne pill of digoxin 0.125mg/day alternate with two pills
of digoxin 0.125/day.
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was significantly lower in patients admitting poor
adherence, and higher in patients with relevant
worsening of the renal function as compared to
other patients.
In the cohort of patients with good adherence
the correlation between the measured and the
predicted SDC was reasonable (r=0.48; P<0.01)
(Figure 2A and B). Furthermore, there was no
Figure 2. Linear-regression analyses and Bland–Altman analyses showing the correlation between the measured and the
predicted SDC (ng/ml) according to the Konishi equation (A and B), the Jelliffe equation (C and D for total body weight, and E
and F for ideal body weight), the Koup and Jusko equation (G and H) and the Bauman equation (I and J). Note that the
Konishi equation shows the best correlation in the linear regression model and less dispersion of the values in the Bland–
Altman plot.
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relevant interaction between the estimated creatinine
clearance and the difference between measured and
predicted SDC (r=0.06; P=0.62), suggesting that the
validity of the Konishi equation seems to apply for a
wide range of renal function, as it was tested in the
current study (Figure 3). Of note, the predicted SDC
was calculated based on the estimated creatinine
clearance at the time of blood sampling for measure-
ment of SDC.
Comparison with other equations
Figure 2 shows the linear-regression analyses and
Bland–Altman analyses describing the correlation
between the measured and the predicted SDCs
for the different tested equations. The Konishi equa-
tion showed a stronger correlation (r=0.48; P< 0.01)
as compared to the other tested equations, including
the Jelliffe equation (r=0.11; P=0.34 for total body
weight, and r=0.12; P=0.34 for ideal body weight),
the Koup and Jusko equation (r=0.28; P=0.03) and
the Bauman equation (r=0.24; P=0.06). A
comparison between themeasured and the predicted
SDCs for the different equations were also tested by
the root mean square error, which again demon-
strated the lowest values, meaning higher accuracy,
for the Konishi equation (Table 4).
No interaction of predicted and measured SDC
with baseline characteristics could be found. Also,
method used to determine SDC and concomitant
medication using including spironolactone did not
influence results (data not shown).
Discussion
The correlation between the measured SDC and the
predicted SDC by the Konishi equation was reason-
able in Caucasian patients with HF. In particular,
more than 9/10 of the measured SDC were within
the therapeutic range of 0.40–1.00 ng/ml in case of
good medical adherence and stable renal function.
The Konishi equation showed a stronger correlation
between the measured and the predicted SDC as
Figure 2. Continued.
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compared to other equations previously validated
for higher SDC-targets, but also as compared to
the most recent equation by Bauman et al., which
was tested for low SDCs in Caucasian patients.
Despite development of more modern drugs,
digoxin is still being used in case of persistence
of HF symptoms on otherwise optimal medical treat-
ment.1,16 Thus, even in the modern era, up to 70%
of HF patients are treated with digoxin.17,18
However, since digoxin has a narrow therapeutic
range and toxic side-effect are expected in case of
over dosage, caution is required when prescribing
this drug and choosing the optimal individual
dosage is of utmost importance. Based on the results
of post hoc analyses of the DIG trial, the therapeutic
range of SDC for HF has been reviewed and lowered
to 0.40–1.00 ng/ml, since patients treated in this
range of SDC had better prognosis as compared to
patients on placebo, while a SDC between 1.0 and
1.2 ng/ml was neural and >1.2 ng/ml even asso-
ciated with increased mortality.1–4,16 However, the
majority of equations used for calculation of the in-
dividual dosage of digoxin, included the one used in
the DIG trial, were developed for higher targets of
SDC.5–7 Recently, Konishi et al. 8 developed a new
equation in Asian HF patients, which was shown to
be more accurate and precise as compared to prior
equations, when targeting a low SDC. Since Asians
and Caucasians may have different pharmacokinetic
of digoxin we aimed to test this equation in a cohort
of Caucasian HF patients.9,10 We specifically
targeted SDCs between 0.40 and 1.00 ng/ml as rec-
ommended by the recent guidelines for treatment of
HF patients.1
The results of the current study confirm the super-
iority of the Konishi equation for predicting SDC as
compared to prior equations also in Caucasian HF
patients. We also compared the Konishi equation
with the Bauman equation, which was recently de-
veloped in Caucasians and tested for low SDCs.
Notably, the current study suggests a better perform-
ance of the Konishi equation as compared with the
Bauman equation for predicting SDC. This may
reveal a weakness of the Bauman equation, which
was developed in a smaller patient cohort, without
rigorous control of the medical adherence and,
more importantly, without testing the equation in a
validation cohort.11
By Konishi equation the individual dosage of
digoxin is calculated based on the target SDC and
the renal function as estimated by Cockcroft–Gault.8
Therefore, this equation can be easily imple-
mented in clinical care, since age, gender and
serum creatinine concentration are the only vari-
ables needed for calculating the individual dosage
of digoxin.
Comparison with prior study
Jones et al. recently tested the equation of Konishi
et al. for prediction of SDC using 36 blood samples
derived from 34 patients treated with digoxin for HF
or atrial fibrillation. Though not specifically men-
tioned, most of the patients were probably
Caucasians, since this study was done in Australia.
In this population a weaker correlation between the
measured and the predicted SDC was found, espe-
cially at low SDCs. However, in this study the ad-
herence to the medical regime was not tested,
timing of blood sampling was not precisely defined
and a large part of patients, especially those with
atrial fibrillation, were treated for higher targets of
SDC.19
Figure 3. Linear-regression analysis between estimated
creatinine clearance (as calculated with the Cockcroft–
Gault equation, ml/min), and differences between
measured and predicted SDC (ng/ml) to test the interaction
of renal function on the performance of the Konishi
equation.
Table 4 Estimated root mean square errors (RMSE)
Equation RMSE, median/Range
Jelliffe–TBW 0.30/0.01–1.19
Jelliffe–IBW 0.20/0.01–1.12
Koup and Jusko 0.25/0.01–1.19
Bauman 0.19/0.00–0.92
Konishi 0.17/0.01–0.75
RMSE, root mean square error; TBW, total body weight;
IBW, ideal body weight.
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Clinical implications
In case of good adherence and stable renal function,
>90% of the measured SDCs were within the
pre-defined therapeutic range and the maximal
measured SDC was 1.00 ng/ml. The numerical cor-
relation between the difference in measured and
predicted SDC, and the estimated creatinine clear-
ance was weak and statistically not significant,
suggesting that there is no relevant shift towards a
worse accuracy of the Konishi equation among
patients with impaired renal function. However,
some patients with worsening of renal function
experienced a significant raise in SDC (see outliers
in Figure 2A and B) with a maximal measured SDC
of 1.70 ng/ml. Notably, these values were higher
than predicted by the Konishi equation even using
creatinine values measured at the time of blood
sampling for measurement of SDC. This could be a
consequence of rapid deterioration of renal func-
tion, non-steady-state conditions of serum creatinine
concentration and, as a consequence, an overesti-
mation of the creatinine clearance by the Corckcrof–
Gault equation. Therefore, considering that chronic
kidney disease is a frequent comorbidity in patients
with HF and renal function may rapidly change,
regular controls of renal function and SDCs are
very important in such patients.
A recent work by Vaz Pe´rez et al.20 suggested that
digoxin therapy may negatively influence medium-
and long-term mortality in patients hospitalized for
acute HF. The association between use of digoxin
and outcome was independent from use of diuretics
and serum creatinine, but not independent from
other clinical factors. Therefore, this association
may be related to sicker patients being more often
treated by digoxin. Still, overdosage of digoxin in
some patients might be another reason. SDCs
during initial hospitalization and long-term
follow-up were unknown, but worsening of renal
function is particularly frequent in patients with
acute HF,21,22 underscoring the importance of moni-
toring of renal function in such patients.
Possibly, the Konishi equation may be used to
further adapt digoxin dose in case of changes in
renal function, but prospective studies are required
to test this. Still, the Konishi equation may be a
useful and simple tool helping physicians to find
the optimal individual dosage when starting digoxin.
As shown in Table 3, dosing of digoxin with the
available pills (0.125 and 0.250mg) may be com-
plex. This is particularly true for patients with
reduced or nearly preserved renal function, where
digoxin dosing changes every second day are neces-
sary. This may negatively influence adherence to the
medical therapy, which in turn is known to affect
prognosis of HF patients.23 In this context, an effort
towards production of digoxin pills with specific
dosages to target ‘lower’ SDCs should be undertaken
by the pharmaceutical companies, in order to sim-
plify digoxin dosing in the daily practice.
Limitations
The small number of patients is a limitation of this
study. Even though patients taking drugs known to
interfere relevantly with the pharmacokinetic of di-
goxin were excluded and adherence to digoxin was
monitored with a specific questionnaire, variation in
the measured SDC due to these reasons cannot be
completely excluded.
Patients with severe renal function were excluded
and patients with normal renal function were under-
represented in the studied population, limiting the
applicability of these results to such patients.
The results of this study are applicable to digoxin
only, since digitoxin has different pharmakokinetic
profiles as compared to digoxin. Therefore, we
cannot provide options to calculate SDC in patients
taking digitoxin based on the data of the current
study. Digoxin is, however, the only cardiac glyco-
sid that has been evaluated in placebo-controlled
trials, and represents therefore the preferred cardiac
glycosid for HF treatment according to the most
recent guidelines.1,2
Just the Konishi equation has been used to calcu-
late the individual dosage of digoxin; the other for-
mulas might have indicated different dosages to
reach the same target concentration. Thus, it
cannot be excluded that these differences could
have an influence on the compared correlations.
Finally, this study did not test the effects of using
this or other equations to predict SDC on outcome.
Further studies should investigate if safety and effi-
cacy may be improved by doing so and which equa-
tion may be best suited.
Conclusion
The results of this study support the clinical validity
and the superiority of the Konishi equation as com-
pared to other frequently used equations for the cal-
culation of the individual dosage of digoxin even in
Caucasian patients with HF. However, regular con-
trol of renal function is recommended to avoid over-
dosage of digoxin, particularly when cardiac and
renal conditions are not stable.
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